View Older Stories

Sep 17, 2026 07:54AM Rhelion unit signs psilocybin supply deal with Dutch research center

Sep 17, 2026 07:52AM Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin

Sep 15, 2026 08:00AM Rhelion unit signs USC supply deal for psilocybin drug candidate

Sep 15, 2026 07:59AM Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the University of Southern California for PEX010 in a Trial for Psilocybin-Assisted Mindfulness

Sep 14, 2026 07:53AM Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs

Sep 10, 2026 07:55AM Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate

Sep 8, 2026 07:52AM Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurologic

Sep 3, 2026 07:39AM Rhelion Life Sciences Confirms Further Delivery of Filament Health's PEX010 to Germany's First Psilocybin Compassionate Use Program

Aug 31, 2026 08:39AM Rhelion Life Sciences Reports First Quarter 2027 Results

Aug 27, 2026 08:24AM Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New United States Patent, Extending the Broadest Natural Psilocybin Patent Estate

Aug 25, 2026 07:22AM Filament Health ships psilocybin drug to UW cancer anxiety trial

Aug 25, 2026 07:20AM Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 for University of Washington Phase 2a Trial in Cancer-Related Anxiety and Depression

Aug 20, 2026 07:39AM Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer's Disease

Aug 19, 2026 08:14AM Rhelion Life Sciences Announces Appointment of Samiuddin Khaja as CFO

Aug 14, 2026 08:16AM Rhelion unit to supply psilocybin for Parkinson's depression trial

Aug 14, 2026 08:14AM Rhelion Life Sciences Signs Agreement with University Health Network for Randomized Clinical Trial of Psilocybin in Parkinson's Disease Depression

Aug 4, 2026 09:00PM Rhelion Life Sciences Corp. Commences Trading Under New Name and Ticker Symbol RHEL on the CSE

Jul 29, 2026 07:53AM Red Light Holland Reports Fiscal 2026 Audited Year-End Results and Provides Update on Rhelion Life Sciences

Jul 17, 2026 07:50AM Red Light Holland Announces Corporate Rebrand to Rhelion Life Sciences Corp

Jul 16, 2026 08:03AM Red Light Holland Announces New Filament Health PEX010 European Research Shipment

Jul 8, 2026 08:00AM Red Light Holland Announces Filament Health's Largest-Ever Manufacturing Run of PEX010, the Standardized and Patented Natural Psilocybin Drug Candidate Trusted Across 80+ Studies Globally, Now Offerin

Jul 7, 2026 08:14AM Filament Health to supply psilocybin drug for veterans PTSD study

Jul 7, 2026 08:12AM Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Military Veterans PTSD Study at ARQ National Psychotrauma Centre

Jun 18, 2026 09:03AM Red Light Holland reports preclinical coca extract results for post-GLP-1 weight management

Jun 18, 2026 09:01AM Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filam

Jun 8, 2026 07:32AM Red Light Holland subsidiary signs psilocybin supply deal with Paris hospital

Jun 8, 2026 07:30AM Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France

Jun 4, 2026 07:30AM Red Light Holland Announces Filament Health's PEX010 Drug Candidate, the Standardized and Patented Natural Psilocybin Trusted Across 80+ Studies Globally, Selected by UCSF for Study Probing Preclinica

May 25, 2026 08:40AM Red Light Holland Expands New Zealand Partnership with Allu Therapeutics to Advance Access to Filament Health's GMP-Compliant PEX010 Botanical Psilocybin Drug Candidate

May 14, 2026 08:30AM Red Light Holland's Wholly Owned Subsidiary, Filament Health, Advances PEX010 Clinical Footprint with New Canadian Academic Studies in Palliative Care, Bipolar II Depression, and Healthy Adult Mechani

May 13, 2026 09:14AM Red Light Holland shareholders approve name change, CFO resigns

May 13, 2026 09:12AM Red Light Holland Announces Shareholder Approval of Name Change and Announces Voting Results from 2026 Annual General and Special Meeting of Shareholders

May 8, 2026 07:30AM Red Light Holland Highlights Publication of Randomized Clinical Trial Showing a Single Dose of Psilocybin Reduced Cocaine Use, with Filament Health Holding the Exclusive License to the Data and Intell

May 7, 2026 07:30AM Red Light Holland's Wholly Owned Subsidiary, Filament Health, Expands Distribution of PEX010 Across Canadian and U.S. Research Institutions

May 4, 2026 08:30AM Red Light Holland Announces Intention to Rebrand

Apr 30, 2026 07:37AM Red Light Holland completes acquisition of Filament Health

Apr 30, 2026 07:30AM Red Light Holland Completes Acquisition of Filament Health, Creating a Global Leader in Psychedelic Drug Development, Commercialization and Distribution

Apr 29, 2026 07:30AM Red Light Holland Announces Filament Health Obtains Final Order for Proposed Arrangement

Apr 27, 2026 07:30AM Red Light Holland Announces Filament Health Shareholder Approval of Acquisition

Apr 24, 2026 08:26AM Red Light Holland Showcases Growing Clinical Demand for Filament Health's PEX010 with New and Repeat University Shipments

Apr 20, 2026 07:30AM Red Light Holland Highlights U.S. FDA-Authorized Study Supporting Multi-Session Psilocybin Therapy using Filament Health's Patented PEX010 Botanical Drug Candidate

Apr 7, 2026 07:30AM Red Light Holland Reports Continued Expansion of Filament Health's PEX010 Clinical Network with New License Agreements and Research Shipments

Apr 1, 2026 09:20AM Red Light Holland to Support University of California San Francisco's Global Psychedelic Study Through Filament Health's Clinical Network

Mar 23, 2026 08:15AM Red Light Holland Announces Filament Health Obtains Interim Order for Proposed Arrangement

Mar 18, 2026 08:15AM Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate

Mar 11, 2026 07:32AM Red Light Holland to acquire Filament Health in all-share deal

Mar 11, 2026 07:30AM RETRANSMISSION: Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation

Mar 10, 2026 04:42PM Red Light Holland to acquire Filament Health in all-share deal

Mar 10, 2026 04:40PM Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation

Mar 3, 2026 08:00AM Red Light Holland Reports Third Quarter 2026 Results and Provides Corporate Update

View Older Stories